|Researchers at Purdue University have developed a new class of compounds that target the main protease (Mpro) in SARS-COV-2/Covid-19 infection.
With the world facing the coronavirus (Covid-19) pandemic, there is an immediate need for intensive protection from the severe acute respiratory illness associated with the disease. Currently, there is no effective pharmaceutical treatment available for SARS-COV-2 infection. These compounds developed by Purdue University researchers are newer modified versions of previous alpha-ketoamide derivatives that have shown potency as anti-viral agents against Covid-19. One of the compounds identified showed potent activity (IC50= 4.2micromolar) in SARS-COV-2 infected Vero-E6 cells.
-Excellent Antiviral Activity Against SARS-CoV-2 in Mammalian Cells
-Improved Drug-Like Properties
-Treatment of Covid-19
-Treatment of Coronavirus
-Pharmaceutical Research & Development
Technology Validation: The compounds have been validated in Vero-E6 cells.
"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication"
Dec 1, 2020
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486